Shopping Cart
Remove All
Your shopping cart is currently empty
In hematological malignancies, CD19, BCMA, and CD22 are the most frequently studied target proteins. CD19 is the primary target for the treatment of B-cell blood cancers. BCMA and CD22 are both antigens expressed on the surface of B cells, and cell therapies targeting these two targets could be used to treat patients with B-cell blood cancers that have developed resistance to cell therapies targeting CD19. Other related targets under study include GPRC5D, CLEC12A and CD7.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.